Replies to post #225571 on Biotech Values

[InTheTrenches]

Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease

Top-line efficacy data expected to be announced during the Third Quarter of 2019

https://www.prnewswire.com/news-releases/neurotrope-concludes-data-collection-in-confirmatory-phase-2-clinical-trial-of-moderately-severe-to-severe-alzheimers-disease-300884499.html

-----

Neurotrope/Oppenheimer KOL Call

Dear Fellow Neurotrope Investors,

We are looking forward to the Alzheimer's Association International Conference in Los Angeles being held July 14-18th 2019. Chief Executive Officer, Dr. Charles Ryan, will be presenting Neurotrope's poster on Wednesday, July 17th at 1:00p Pacific time. The poster will be available from 9:30 AM-4:15PM that day.

Following the AAIC, Neurotrope's Chief Scientific Advisory Board members Dr. Martin R. Farlow and Dr. Marwan Sabbagh will be hosting a KOL call with Oppenheimer's Biotech team. Dr. Farlow is a Professor Emeritus in the Department of Neurology and co-director of the Alzheimer's Disease Center at Indiana University. Dr. Sabbagh is the director of the Cleveland Clinic Lou Ruvo Center for Brain Health.

The call will take place immediately following the AAIC meeting.

Oppenheimer's Biotech Team invites you to a Conference Call:
Alzheimer Experts Provide Insights on Recent Data

When: Friday July 19, 2019
Time: 11:00 AM Eastern Time

Dial in Numbers:
US/Canada [phone], passcode 2687039
International [phone], passcode 2687039

Sincerely,

Susan Roberts
[e-mail]
202-779-0929